Sangeet Ghai, MD, FRCR

Sangeet Ghai, MD, FRCR

University of Toronto

Toronto, Ontario, Canada

Dr. Sangeet Ghai is the Deputy Chief of Research and Associate Professor in the Joint Department of Medical Imaging (JDMI) at the University of Toronto in Ontario, Canada. He is affiliated with the Cancer Clinical Research Unit at the Princess Margaret Cancer Centre, also in Toronto. Dr Ghai completed his postgraduate training in India, including a senior residency at the All India Institute of Medical Sciences in New Delhi. His main areas of interest and research include prostate imaging and intervention. He is actively involved in developing prostate MRI techniques, high-resolution ultrasound imaging of the prostate, and in-bore focal treatments for intermediate-risk prostate cancer. He is also interested in MR-guided focused ultrasound surgery and MR-guided focal laser ablation.


Talks by Sangeet Ghai, MD, FRCR

Radiologic Perspective on the Clinical Utility of and Emerging Data on Micro-Ultrasound

In part 1 of a 2-part series on micro-ultrasound for prostate cancer imaging, Sangeet Ghai, MD, FRCR, Deputy Chief of Research and Associate Professor in the Joint Department of Medical Imaging (JDMI) at the University of Toronto in Ontario, Canada, considers micro-ultrasound and data evaluating its ability to produce better results than conventional imaging from a radiologic perspective. He explains that micro-ultrasound is a system that functions on a higher frequency than conventional options and uses the PRIMUS protocol, a prostate risk identification system similar to PIRADS. Dr. Ghai states that micro-ultrasound has been shown to increase detection rates by 12%, have sensitivity as high as 91%, and find cancer that was missed by MRI. He also discusses data comparing micro-ultrasound to other imaging modalities that shows that micro-ultrasound can find 1.05 times as much grade group 2 and higher disease as multiparametric MRI and has a 14.6% higher detection rate than robotic elastic fusion. Dr. Ghai concludes by reviewing data looking at micro-ultrasound visibility of MRI lesions and real-time targeting showing that 90% of MRI lesions were visible on micro-ultrasound and that 61% of those harbored clinically significant prostate cancer (csPCa) on targeted biopsy, that 43% of MRI lesions were retrospectively visible on TRUS and that 58% of those harbored csPCa, and that 24% of micro-ultrasound lesions with normal MRI were positive for csPCa.

Read More

Current and Emerging Imaging Tools for Improving Risk Assessment, Selection of Patients for Biopsy, and Tissue Sampling

Sangeet Ghai, MD, FRCR, Associate Professor of Abdominal Imaging at Toronto General Hospital, outlines improvements in ultrasound technology that could significantly improve real-time prostate cancer diagnostics. He discusses several studies demonstrating the diagnostic capability of the 29Mhz microultrasound, how it compares to mpMRI, and how this new technology could streamline prostate cancer diagnostics by reducing the need to conduct MRI fusion biopsies.

Read More

Join the GRU Community

- Why Join? -